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I . SUMMARY
Twenty-two cases of paralytic poliomyelitis with 3 deaths were reported in the 
United States in 1972. This represents an increase of 3 cases from the corrected total 
of 19 cases reported for 1971. The cases were scattered among 14 states. Connecticut 
and New York with 4 cases each-, and Texas with 3. cases, were the only states to report 
more than 1 case. Seventeen (78%) of the 22 cases were in persons 19 years of age or 
younger, and 5 (23%) were in preschool age children. Type 1 poliovirus was implicated 
in 64% of the cases, and in 74% of those cases in which an etiology was determined. Four 
of the 22 reported cases were "recipient vaccine-associated" and 6 were "contact vaccine- 
associated." Two additional cases of paralytic poliomyelitis were reported for 1971 and 
were both "contact vaccine-associated," increasing the 1971 total to 19 cases, 10 of which 
were "contact vaccine-associated." This is the highest annual number of "contact vaccine- 
associated" cases reported to CDC since live, attenuated oral poliovirus vaccine became 
widely used in 1962. None of the persons who contracted paralytic poliomyelitis in 1972 
gave a history of having received adequate polio immunization.
The 1972 National Immunization Survey showed a continuation of the downward trend 
in the percent of preschool age children who received at least 3 doses of either oral 
poliovaccine or inactivated poliovaccine. The general trend of a decreasing Dercentage 
of persons with adequate polio immunizations occurred in all age groups.
II. EPIDEMIOLOGY OF PARALYTIC POLIOMYELITIS
This 18th Annual Poliomyelitis Surveillance Report, published by Neurotropic 
Diseases, Viral Diseases Division, CDC, summarizes selected epidemiologic and laboratory 
characteristics of the reported cases of poliomyelitis for 1972. These data are based 
on official reports from the states to the Bureau of Epidemiology, CDC.
In 1972, the "best available paralytic poliomyelitis case count" was 22 cases.
This terminology, used since 1958 as the best available representation of the number 
of cases of paralytic illness of poliovirus etiology, includes those clinically and 
epidemiologically compatible cases known to have residual paralysis at 60 davs, plus 
those cases reported initially as paralytic poliomyelitis for which no 60-day report 
on residual paralysis was available. Limitation of the summary count to those cases 
with proved residual paralysis permits exclusion of cases with more transient weakness 
possibly due to echovirus, Coxsackie virus, or other etiologies. Twenty-one of the 22 
paralytic cases reported for 1972 had pathologic, serologic, or virologic supporting 
evidence for the diagnosis of poliomyelitis. Follow-up reports from 1 to 6 months after 
onset of illness were submitted for the 19 surviving cases; residual paralvsis was pre­
sent in all 19 cases.
A. Characteristics of the Cases
The total number of cases included in the "best available paralytic poliomyeli­
tis case count" has declined since this number was first tabulated in 1958 (Figure 1).
The 22 cases reported in 1972 represents the third lowest annual total reported to CDC 
since initiation of surveillance in 1955. In 1972, cases occurred throughout the year, 
with 10 cases occurring in October ^Figure 2); 8 of the 10 were clustered in 1 outbreak. 
The classic summer-fall peak, last observed in the early 1960s (Figure 3), has not 
persisted.
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Fig. /  "BEST AVAILABLE PARALYTIC POLIOMYELITIS CASE 
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Fig. 2  PARALYTIC POLIOMYELITIS, BY ONSET, U-S. A., 1972
Fig. 3 PARALYTIC POLIOMYELITIS CASES, BY MONTH OF ONSET, UNITED STATES, 1962-1972
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Geographic distribution of cases by county of residence (Figure 4) shows that cases 
were scattered among 14 states. Connecticut and New York with 4 cases each, and Texas 
with 3 cases, were the only states reporting more than 1 case. One case was temporally 
related to travel to Mexico. None of the other cases were related to known travel to 
endemic areas.
Residual paralysis in the cases parallels that reported for the past 4 years 
(Table 1). Comparison of age distribution for the past 11 years is presented in Table 2. 
In 1972, 17 of the 22 cases (77%) were in persons 19 years of age or younger; 5 of these 
cases (23%) were in preschool age children. This represents a change from the 1971 
distribution of 47% of the cases in adults and 42% in preschool age children.
Table 1
Paralytic Poliomyelitis by Status of Residual Paralysis at 60 Days*, 1968-1972
1968 1969 1970 1971 1972
Status Cases _% Cases % Cases % Cases _% Cases _%
Death 5 10 0 0 2 6 2 12 3 14
Severe Residual 8 17 4 22 1 3 3 12 5 23
Significant Residual 18 38 11 58 21 66 9 53 9 41
Minor Residual 10 21 3 15 3 10 3 12 5 23
Unknown 7 14 1 5 6 15 2 12 0 0
Total 48 100 19 100 33 100 19 100 22 100
*In 1971 and 1972, the status of residual paralysis is based on 1- to 11--month follow-
up reports
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T a b le  2
Paralytic Poliomyelitis Cases, by Age Group, 1962-1972
1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972
Age Group i i _% a % a % it % a % a % ii % a % a % // % a %
0- 4 338 49 165 49 38 42 31 51 79 77 25 61 31 65 9 46 30 97 8 42 5 23
5- 9 139 20 60 18 16 17 10 16 10 10 2 5 3 6 2 11 2 6 0 - 1 5
10-14 70 10 38 11 7 8 7 11 3 3 0 - 4 9 1 5 0 - 0 - 3 14
15-19 26 4 15 4 8 9 2 3 1 1 1 2 1 2 4 22 0 - 2 11 8 36
20-29 52 8 24 7 7 4 4 7 3 3 4 10 4 8 0 - 0 - 3 16 1 5
30-39 36 5 18 5 7 8 3 5 5 5 7 17 2 4 2 11 0 - 5 26 3 14
40 + 22 3 8 2 11 12 4 7 1 1 2 5 3 6 1 5 1 3 1 5 1 5
Unknown 8 1 8 2 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -
Total 691 336 91 61 102 41 48 19 33 19 22
B. "Type Specific Etiology" of Poliovirus Associated with Paralytic Cases
The basis for establishing a type specific etiology for the 1972 paralytic polio­
myelitis cases is summarized in Table 3. Seventeen of the 22 cases were of known etiology; 
2 of the 17 were confirmed by both viral isolation and diagnostic (4-fold) rise or fall 
in antibody titer, and 5 were confirmed by serology alone. Although the presence of an 
enterovirus in the alimentary tract does not constitute proof of an etiologic role, 
isolation of poliovirus from throat washings or stool specimens in the context of 
compatible illness and absence of evidence for another etiology has been accepted by the 
respective states as adequate documentation of etiology, and is indicated as the probable 
agent in 9 cases. In 1 case, the diagnosis of type 1 paralytic poliomyelitis was based 
on clinical and epidemiologic criteria alone. This case was 1 of 8 cases documented as 
type 1 poliovirus clustered at a boarding school in Connecticut, and a single serologic 
test indicated an elevated polio type 1 neutralizing antibody.
Table 3
Paralytic Poliomyelitis
by Designation of Known "Etiologic" Poliovirus Type, 1972*
Poliovirus
Basis of Confirmation Type 1 Type 2 Type 3 Total
Viral isolation and 0 0 2 2
diagnostic serology
Serology (only) 4 0 1 5
Viral isolation (only) 9 0 0 9
Diagnosis made on
clinical and epidem-
iologic basis only 1 0 0 1
Total 14 0 3 17
*Excludes 4 vaccine-associated cases with multiple isolates or serologic 
changes
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Comparison of "etiologic" poliovirus types for 1966-1972 (the only years for which 
this method of definition has been used) shows that in 1972, type 1 poliovirus increased 
from the lowest level of 26% in 1971 to 64%, the second highest percentage since 1966. 
However, for the first time in 7 years, type 2 poliovirus was not implicated as the etio­
logic agent in any of the reported cases (Table 4).
Table 4
Paralytic Poliomyelitis Cases 
by "Etiologic" Poliovirus Types, 1966-1972
Poliovirus_________________  Multiple*
Type 1 Type 2 Type 3 Unknown Types
Year _± %_ _# %_ _# %_ _# %_ _# %_ Total Cases
1966 60 59 13 13 6 6 23 22 - 102
1967 18 44 8 19 7 18 8 19 - 41
1968 27 56 7 15 4 8 10 21 - 48
1969 6 32 5 26 4 21 4 21 - 19
1970 28 85 4 12 1 3 0 0 - 33
1971 5 26 6 32 6 32 2 11 _ 19
1972 14 64 0 0 3 14 1 5 4 18 22
*Multiple types implicated by isolation and serology in vaccine-associated cases
Tabulation of the 22 paralytic cases by age group and "etiologic" virus type 
shows that 17 of the 22 cases (78%) were under 20 years of age (Table 5). Thirteen of 
the 17 (76%) had type 1 polio and 13 of the 22 (59%) were concentrated in the group of 
less than 20 years of age with type 1 polio. Eight of the 13 cases occurred in 1 
outbreak.
Table 5
Paralytic Poliomyelitis Cases 
by Age Group and "Etiologic" Poliovirus Type, 1972
Poliovirus
Age Group Type 1 Type 2 Type 3 Multiple Types Unknown Total
0-4 3 0 0 2 0 5
5-19 10 0 0 2 0 12
20-29 0 0 1 0 0 1
30-39 0 0 2 0 1 3
40 + 1 0 0 0 0 1
Total 14 0 3 4 1 22
6
C. Viral Isolations Associated with Paralytic Poliomyelitis Cases
The number of cases in which viral isolations were attempted and the number in 
which isolation attempts were successful for the period 1961-1972 are shown in Table 6. 
Samples for viral isolation were obtained in a higher percentage of cases in 1970, 1971, 
and 1972, than in each of the previous 9 years. This probably reflects a continuing 
increased utilization of laboratory testing to confirm clinical impressions.
Table 6
Paralytic Poliomyelitis Cases by Number of Specimens Submitted 
and Results of Virus Isolation Attempts, by Year, 1961-1972
Year
Best Available 
Paralytic 
Case Count
Cases with Specimens 
Submitted for Isolation
Cases
Poliovirus
With
Isolated
% of Specimens 
Submitted in 
Which Isolation 
SuccessfulNo. % No. %
1961 829 481 58.0 382 46.1 79%
1962 691 472 68.3 408 59.0 86%
1963 336 242 72.0 19 7 58.6 81%
1964 91 77 84.6 51 56.0 66%
1965 61 50 81.9 38 62.3 76%
1966 103 82 79.6 74 71.8 90%
1967 40 31 77.5 29 72.5 93%
1968 48 39 81.2 35 72.9 90%
1969 19 16 84.2 14 73.7 88%
1970 33 33 100.0 31 93.9 94%
1971 19 17 89.5 14 73.7 82%
1972 22 20 90.9 15 75.0 68%
Twenty of the 22 patients submitted specimens for poliovirus isolation. Speci­
mens submitted from 19 of 20 included a stool specimen or rectal swab. An isolate was 
obtained from 13 of the 19 specimens. Four cases had positive throat cultures, and 
poliovirus was isolated from the brain of 1 fatal case. None of the 6 cerebrospinal 
fluid (CSF) samples was positive, and 1 of the 3 urine samples yielded an isolate. A 
comparison of the frequency of isolation of each poliovirus type from the annual total 
of paralytic cases for the years 1961-1972 is shown in Table 7.
Table 7
Paralytic Poliomyelitis Cases by Type of Poliovirus Isolated 
and Percentage of Isolates by Year, 1961-1972*
Number of Isolates______ Percentage of Isolates
Poliovirus Type Poliovirus Type
Year 1 2 3 Unknown 1 2 3
1961 231 6 145 0 60.5 1.6 37.9
1962 300 8 100 0 73.5 2.0 24.5
1963 160 6 31 0 81.2 3.0 15.7
1964 21 6 24 0 41.1 11.8 47.0
1965 19 8 11 1 50.0 21.1 28.9
1966 55 13 6 1 74.3 17.6 8.1
1967 16 6 7 0 55.2 20.7 24.1
1968 25 7 3 0 71.4 20.0 8.6
1969 5 5 4 0 34.6 34.6 30.8
1970 26 4 1 0 83.9 12.9 3.2
1971 5 4 5 0 35.7 28.6 35.7
1972 ll1,2 l1 61,2 0 61.1 5.5 33.3
*Includes vaccine-associated cases with multiple isolates
1Includes 1 case with isolates of all 3 types
2Includes 1 case with isolates of types 1 and 3
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D. Epidemic of Poliomyelitis, Greenwich, Connecticut, 1972
From September 29 through October 13, 1972, 11 cases of poliomyelitis occurred 
in students attending a Christian Science boarding school in Greenwich, Connecticut 
(Figure 5), Eight of the 11 cases were paralytic and 3 were nonparalytic. None of the 
8 students with paralytic poliomyelitis had been previously immunized with either 
inactivated polio vaccine (IPV) or oral poliovaccine (OPV); 1 of the 3 students with 
nonparalytic polio had received 2 IPV and all 3 types of monovalent oral poliovaccine 
(MOPV) 9 years previously. The age distribution among cases was from 7-18 years of age. 
Nine cases were in males and 2 in females. Residual at 60 days demonstrated severe 
paralysis in 2 cases. Isolates were obtained from 7 of the 11 cases, and all were com­
patible with wild virus origin. The 4 cases with no isolate had an elevated serologic 
titer to type 1 poliovirus.
Fig. 5  PARALYTIC POLIOMYELITIS CASES, DAYCROFT SCHOOL, GREENWICH 
CONN., 1972
SEPTEMBER | OCTOBER
ONSET (2-DAY PERIOD)
This epidemic represents the potential for epidemics of poliomyelitis to occur 
in unimmunized populations.
E. Association of Immunization with Paralytic Poliomyelitis
1. Paralytic Poliomyelitis in Recent Vaccine Recipients
In July 1964, the Surgeon General's Special Advisory Committee on all polio­
myelitis vaccine reviewed all cases of paralytic disease consistent with poliomyelitis 
that had occurred within 30 days following receipt of all OPV. At that time, 57 cases 
were judged to be compatible with vaccine association by virtue of meeting the following 
criteria:
a. Onset of illness between 4 and 30 days following feeding of the specific 
vaccine, plus onset of paralysis not sooner than 6 days after the feeding.
b. Significant residual lower motor neuron paralysis.
c. Laboratory data not inconsistent with respect to multiplication of the 
vaccine virus fed.
d. No evidence of other motor neuron disease, definite sensory loss, or 
progression (or recurrence) of paralytic disease 1 month or more after onset.
Since 1964, the vaccine-associated cases have not been formally reviewed by 
the Special Advisory Committee. However, cases have been individually classified by CDC 
as vaccine-associated on the basis of compatibility with the above criteria and relation­
ship to the underlying disease state (e.g. hypogammaglobulinemia) and available 
laboratory isolation and serologic results. (See Section III for discussion of 
laboratory testing.)
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Four additional cases of recipient vaccine-associated polio occurred in 1972 
(Table 8). One was in an 18-year old male who had a vaccination history of receiving IPV 
in the 1960s and 1 trlvalent oral poliovaccine (TOPV) in 1972. Twelve days after receipt 
of his second dose of TOPV, he became ill and was left with severe residual at 60 days. 
Type 3 poliovirus was isolated from the stool, throat, and urine, which was intermediate 
in its antigenic characteristic and had a +/+ RCT characteristic at 39.2°C and 39.9°C, 
respectively. These findings were not incompatible with a vaccine strain. In addition, 
a type 1 poliovirus was isolated from the throat which had a vaccine antigenic character­
istic and by RCT characterization, was -/- at 39.2°C and 39.9°C, respectively. This 
isolate was almost certainly vaccine type.
Table 8
Paralytic Disease in Oral Vaccine Recipients
Date of Prior Type Vaccine
Interval 
to Onset Isolate
Residual
Disability
State Age Sex Onset IPV OPV Administered of Symptoms Type Characteristic* 60 Days
Iowa 18 years Male 10/8/71 1 (1960s) 1 (1972) TOPV 12 days 1 vaccine
-/-
severe
3 intermediate
+/+
Maine 2 years Male 5/22/72 0 0 TOPV 2-4 days 2 vaccine
-/-
significant
3 vaccine
+/+
Oregon 9 months Male 12/31/72 0 1 (10/72) TOPV 4 days 1 vaccine significant
2 wild
3 vaccine
+/-
New
York
10 months Male 5/27/72 0 1 (10/71) TOPV 75 days 1 wild
+/+
death
*Strain characterization by modified wecker serodifferentiation and RCT characteristics
The second case occurred in a 2-year-old male who had no previous vaccination 
history. He became ill approximately 4 days following receipt of the vaccine. He was left 
with significant residual at 60 days. Types 2 and 3 polioviruses were isolated from the 
stool; the type 2 isolate was vaccine-like and the type 3 isolate was not incompatible 
with a vaccine-like virus.
The third case occurred in a 9-month-old male who had received TOPV 4 days 
before the onset of symptoms. All 3 poliovirus types were isolated from the stool; types 
1 and 3 were vaccine-like and type 2 was found to have an MPB of 41.9 and an RCT of -/-.
The fourth case occurred in a 10-month-old male who had hypogammaglobulinemia. 
Both the patient and his sibling received TOPV in March 1972. Seventy-five days later, on 
May 27, 1972, the onset of symptoms began with a respiratory-like illness with progression 
to coma and death on June 1, 1973. Polio type 1 was isolated from the brain and stool, 
with an MPB of 43 and an RCT of +/+.
With the addition of these 4 cases, the total number of recipient vaccine- 
associated polio cases reported to CDC from July 1964 to December 1972 is now 20 cases.
2. Paralytic Poliomyelitis in Contacts of Recent Vaccine Recipients
In addition to the group noted above, it has been recognized that cases of 
paralytic illness have also occurred in persons with a history of close relationships 
to OPV recipients. The working definition of a contact vaccine-associated case specifies 
that onset of illness shall have occurred between 4 and 60 days following feeding of the 
specific vaccine in question to the recipient in contact with the case, and that the case
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shall have had contact with the recipient within 30 days prior to the onset of illness.
In addition, criteria b., c., and d. in the definition of a "recipient vaccine- 
associated" case also applies. This definition of "contact vaccine-association" does 
not require isolation of a vaccine-like virus from the case. Persons with a vaccine-type 
poliovirus isolate but with no history of contact are described as "community contact" 
cases.
Six "contact vaccine-associated" cases were reported for 1972 (Tables 9 and 
10). Four of the cases occurred in adults living with children who had received routine 
TOPV. The remaining 2 cases had polio with a vaccine-type isolate but no known contact 
with recently immunized persons (Table 10). Four of the 6 cases occurred in persons 
with no history of prior polio immunization; the other 2 had received only IPV. In 
5 of the 6 cases with poliovirus isolated, 3 were type 3 and 2 were type 1.
Table 9
Paralytic Disease in Close Contacts of Vaccine Recipients, 1972
State Age Sex
Prior
Immuniz
Contact
Relation- Vaccine 
ship Administered
Interval 
Administered 
to Onset
PT's
Isolate
Type
Antigenic 
and RCT* 
Characteristic
4-Fold
AB
Change
Residual
Disability
Texas 35 M 0 son TOPV 51 days 3 Non-Vaccine
±/-
1,2,3 death
Florida 21 F 0 baby TOPV 26 days 3 Vacc-like
+/±
3 severe
Georgia 30 M 0 daughter TOPV 23 days none - no
change
significant
Indiana 18 M 1-IPV nephew TOPV 48 days 1 Vacc-like no
change
minor
*RCT performed at 39.2°C and 39.9°C
Table 10
Paralytic Disease in "Community Contacts," 1972
State Age Sex
Prior
Immuniz
Contact
Relation- Vaccine 
ship Administered
Interval 
Administered 
to Onset
PT's
Isolate
Type
Antigenic 
and RCT* 
Characteristic
4-Fold
AB
Change
Residual
Disability
Wisconsin 18 F 0 none unknown unknown 1 Vacc-like no
change
severe
Texas 12 M 1-IPV none unknown unknown 3 Vaccine 1,2 minor
*RCT performed at 39.2°C and 39.9°C
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3. Rates of Vaccine-Associated Paralytic Polio in OPV Recipients and Their Contacts
The experience*' of recipients and their contacts with respect to developing 
vaccine-associated paralytic disease can be expressed in terms of rates of cases per mil­
lion doses of vaccine distributed (Table 11). These statistics provide a useful basis for 
comparing trends. However, these rates do not accurately reflect the risks to recipients 
or their contacts because there are no satisfactory estimates of the number of doses 
actually received or the number of susceptible persons who come in contact with vaccine 
recipients. These rates are divided into 2 periods, 1961-1964 and 1965-1971. Beginning 
in 1965, a general curtailing of routine immunizations for adults was recommended by the 
Advisory Committee on Immunization Practices (ACIP), followed by a shift in emphasis from 
mass immunization campaigns and community-wide programs to routine immunization of infants; 
TOPV became the most widely used oral poliovirus vaccine.
Table 11
Rates of Vaccine-Associated Paralytic Polio in Known Recipients and 
Their Contacts, United States, 1961-1972
Est. Doses
Distributed Recipient Recipient Contact Contact
Vaccine Period in Millions Cases Rate/Million Cases Rate/Million
MOPV-1 1961-64
*•1965-72
109* 16 0.147 0 0
8.76 1 0.114 2 0.228
MOPV-2 1961-64
*■1965-72
104* 2 0.019 0 0
6.96 0 0 2 0.287
MOPV-3 1961-64
*1965-72
105* 39 0.371 3 0.029
7.46 6 0.804 0 0
All MOPV 1961-64
*1965-72
318* 57 0.179 3 0.009
23.2 7 0.302 4 0.172
TOPV 1961-64
*1965-72
28.2 5 0.177 0 0
182 8 0.033 38 0.209
All OPV 1961-64
*1965-72
346 62 0.179 3 0.009
205 15 0.063 42** 0.205
*Sources of distribution data: state health departments and PHS regional offices
prior to June 1962, and the Biologic Surveillance Unit, CDC, subsequently 
**Includes 1 case for which type of vaccine administered to recipient is unknown
As noted in the 1971 Annual Poliomyelitis Surveillance Report, since 1964, 
there has been a statistically significant decrease in the rate of vaccine-associated 
cases in vaccine recipients (p<.0001) and a statistically significant increase in this 
rate for contacts of vaccine (pc.OOOl). The theory was proposed that the significant 
increase in contact cases was due to both the shift in emphasis from mass immunization 
campaigns to routine immunization of infants, and to a presumed improvement in recogni­
tion of contact cases, facilitated by the reduction of the total number of poliomyelitis 
cases following the 1961-1964 polio immunization campaigns. The contact cases which 
occurred in 1972 were consistent with this theory since 4 of the 6 unimmunized persons 
had contact with immunized infants. In the other 2 cases, there was no history of 
contact with recently immunized persons.
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4. Vaccine Failures
A "vaccine failure" is presently defined as paralytic disease attributed to 
poliovirus infection occurring in an individual having previously received an "adequate 
immunization series." As defined by the ACIP, an adequate series consists of 4 or more 
doses of IVP, 3 doses of MOPV plus 1 dose of TOPV, or 3 doses of TOPV at appropriate 
intervals (see Appendix). Four of the 22 paralytic cases reported for 1972 had received 
only 1 OPV dosage prior to onset of illness (Table 12). These 4 cases bring to 78 the 
total number of persons reported since 1963 to have received at least 1 dose of OPV prior 
to onset of paralytic poliomyelitis. Of the 7 isolates obtained from these 4 patients,
4 were type 1 and 2 were type 3. Sixteen of the 22 patients had received no previous 
immunization, and 3 of the 22 had received only 1 previous dose of IPV.
Table 12
Paralytic Poliomyelitis by Immunization Status 
of All Persons With History of at Least 1 Immunization, 1972
State Age Sex
Prior
TOPV
Doses
Year of 
Last OPV 
Dose
Prior
IPV
Doses
Year of 
Last0IVP 
Dose
Virus Type 
Implicated
Residual
Disability
Texas 12 years M 0 - 1 1967 3 minor
Virginia 50 years M 1 1963 0 - 1 minor
New York 10 months M 1 1971 0 - 1 death
Iowa 18 years M 1 1972 1 1960 1,3 severe
Indiana 18 years M 0 - 1 1962 1 minor
Oregon 9 months M 1 1972 0 - 1,2,3 significant
III. LABORATORY STUDIES OF POLIOMYELITIS
A. Characterization of Poliovirus Isolations
Laboratory techniques have been employed to differentiate "vaccine-like" from 
"nonvaccine-like" strains of virus isolates. One of these tests, the modified Wecker 
intratypic serodifferentiation test, is based upon certain antigenic characteristics 
of the virus strains. Another test, the "temperature marker" ("T" marker) is based upon 
comparison of viral replication at different temperatures. In general, strains of polio­
virus types 1 and 2 that are antigenically "vaccine-like" are usually associated with 
negative "T" markers, while this association is seen less frequently with poliovirus 
type 3. These tests can establish the origin of the virus isolated with some degree of 
probability. However, because certain wild type 3 viruses are antigenically "vaccine­
like," and because of the known antigenic and "T" marker changes which can occur, 
especially with vaccine type 1 virus, these tests do not definitely establish the origin 
of the virus isolated. Furthermore, these tests do not in any way indicate the neuro- 
virulance of the isolated virus.
Laboratory characterization studies were performed by the Enteric Virology Branch, 
Bureau of Laboratories, CDC, on 19 isolates from 15 patients with paralytic poliomyelitis 
reported in 1972 (Table 13).
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Table 13
Classification of Isolates by Wild or Vaccine-Associated Disease, 1972
RCT Characteristics
Epidemiologic Polic• Virus Antigenic 39.2°
Type
Wild
State Age Sex Data Type Characteristics 39.9°
Connecticut 16 years M (See Section II.D.) 1 Nonvacc-like +/+
Massachusetts 18 years M 1 Nonvacc-like +/+
New York 15 years M 1 Nonvacc-like +/+
Connecticut 17 years M 1 Vacc-like +/+
New York 15 years M 1 Nonvacc-like +/+
Connecticut 7 years F 1 Nonvacc-like +/+
Vaccine- Iowa 18 years M Recipient 9/26, 1 Vaccine
Associated onset interval 3 intermediate +/+
Recipient 12 days
Maine 2 years M Recipient dose 2 Vacc-like • +/+
2, 5/18, onset 
interval 4 days 3 Vacc-like +/+
New York 10 months M Hypogammaglobulinemia 
recipient 3/72 
contact 3/72 
onset interval 75 days
1 Nonvacc-like +/+
Vaccine-
Associated
Texas 12 years M No contact known 3 Vacc-like
Contact Florida 21 years F Contact 5 months 
baby, 26 day onset 
interval
3 Vacc-like +/+ -
Indiana 18 years M Nephew, onset 
interval 48 days
1 Vacc-like
Wisconsin 18 years F No contact known 1 Vacc-like
Texas 35 years M 4 month son, 5 day 
onset interval
3 Nonvacc-like + -/+
Oregon 9 months M recipient - 4 day 1 Vaccine
interval 2 Wild
3 Vaccine + -/-
B. Poliovirus Isolations. 1972
Reports of 150 poliovirus isolations were received from state reporting labora­
tories in 1972. Only 13 (8%) were associated with paralytic disease, whereas 28 (19%) 
were in persons with aseptic meningitis and/or encephalitis (Table 14). Each of the 3 
types were isolated with similar frequency.
Table 14
Poliovirus Isolations, by Type and Clinical History 
United States 1972
Clinical History Type....1 Tvoe 2 Type 3 Total
Associated with 
Paralytic Disease
7 2 4 13
Associated with
Aseptic Meningitis 
and/or Encephalitis
11 9 8 28
Other 29 30 16 75
Unknown 10 15 9 34
Total 57 56 37 150
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C. The 1972 Immunization Survey
A second approach to estimating immunization levels In the population involves 
a sample survey of the history of types and doses of vaccine received.* While this 
questionnaire method is not as accurate as serologic surveillance, it has proved useful 
in assessing the proportion of the population that can be expected to exhibit immunity 
to poliovirus infection. Table 15 shows the percentage of the population under 15 years 
of age, by age group, that received at least 3 doses of either OPV or IPV and the per­
centage that received no poliovaccine whatsoever from 1965-1972.
Table 15
Poliovaccine Immunization Status by Age Group (Under 15 Years)
United States 1965-1972
Percentage with _> 3 doses Percentage with no OPV or
of OPV or ^  3 doses of IPV IPV Immunization
Age Group Age Group
Year 1-4 5-9 10-14 1-4 5-9 10-14
1965 73.9 89.9 92.1 9.9 3.0 2.1
1966 70.2 88.2 90.0 11.3 2.9 2.3
1967 70.9 88.3 89.7 11.7 3.1 2.2
1968 68.3 84.9 87.8 10.5 3.3 2.2
1969 67.7 83.6 85.7 10.2 3.2 2.5
1970 65.9 82.3 85.3 10.8 3.6 2.3
1971 67.3 81.2 83.9 8.6 3.3 2.6
1972 62.9 78.9 81.8 10.7 3.9 3.2
The decline noted from 1965-1970 in the percentage of preschool age children 
who received at least 3 doses of either OPV or IPV recurred in 1972, following a slight 
plateau in 1971. A decreasing level in the percentage with adequate immunization occurred 
in all age groups. The 5-9 and 10-14 year age groups had the highest percentage with no 
OPV or IPV since 1965, and the percent in the 1-4 year age group also increased over 1971.
IV. VACCINE DISTRIBUTION AND VACCINATION STATUS OF THE POPULATION
Two kinds of information indicative of the vaccination status of the United States 
population are available. One is the number of doses of poliovaccine distributed 
annually in the United States. These data, as summarized for 1962-72 in Table 16, 
present not the number of doses administered, but the maximum possible utilization.
More importantly, these data show certain trends in immunization practice. Clearly,
TOPV was the only vaccine being utilized in significant quantities in 1972.
*United States Immunization Survey, September 1972
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Table 16
Poliomyelitis Vaccines, Net Doses (Millions) Distributed Annually 
United States 1962-1972
Year
Poliomyelitis Vaccine 1962* 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972
Inactivated (IPV) 
Live, Oral (OPV)
15.3 19.0 8.8 7.5 5.5 4.0 2.7 *** *** *** ***
Monovalent (MOPV)
Type 1 33.1 38.7 24.9 4.7 1.4 1.3 0.5 0.5 .3 .2 ***
Type 2 37.0 34.2 29.8 3.4 1.3 0.9 0.5 0.9 .2 .1 ***
Type 3 13.7 54.2 28.4 3.7 1.4 1 . 0 0.6 0.4 .3 .2 ***
Trivalent (TOPV) 4.2** 24.0 17.4 24.0 18.0 23.9 22.5 25.8 25.5 24.7
Total 99.1 150.3 115.9 36.7 33.6 25.2 28.2 23.7 26.6 25.9 24.7
*July-December (Biologies Surveillance Program began in July 1962) 
**Production began in mid-1962 
***Not shown since fewer than 3 distributors reported
V. ADDENDUM - ADDITIONAL CASES OF PARALYTIC POLIOMYELITIS REPORTED FOR 1971
Two additional "contact vaccine-associated" cases occurring in 1971 were reported to 
CDC following publication of the 1971 Annual Poliomyelitis Surveillance Report. This 
increases the total to 10 "contact vaccine-associated" cases for 1971, the highest number 
reported since 1964. The first case was in a 20-year-old female from Indiana with a 
history of 2 previous doses of IPV and no previous OPV, who came in contact with her 
recently vaccinated 6-month-old child. The date of onset was 35 days after the 
vaccination of the child with TOPV. Stool and nasal swabs did not yield an isolate, 
but there was a rise in titer to type 3 poliovirus.
The second case was in a 29-year-old female from Illinois with no previous immuni­
zation history, who came into contact with her recently vaccinated infant. Onset of 
illness was 19 days following the child's immunization with TOPV; the mother was left 
with minor residual at 60 days. No isolate was obtained from the mother, and a serologic 
rise to type 2 occurred.
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RECOMMENDATION OF THE PUBLIC HEALTH SERVICE 
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
POLIOMYELITIS VACCINE
INTRODUCTION
Widespread use of poliovirus vaccines since 1955 has 
resulted in the virtual elimination of paralytic 
poliomyelitis in the United States. To ensure continued 
freedom from the disease, it is necessary to pursue 
regular immunization of all children from early 
infancy.
Paralytic poliomyelitis declined from 18,308 cases 
in 1954 to 32 cases in 1970 and 19 cases in 1971. A 
national survey in 1971 showed that 77 percent of 
individuals 1-19 years old had received at least 3 doses 
of oral poliovirus vaccine*(OPV), inactivated poliovirus 
vaccine**(lPV), or both.
Nevertheless, low immunization rates still prevail in 
certain disadvantaged urban and rural groups, 
particularly for infants and young children born since 
the mass immunization campaigns conducted between 
1958 and 1962. Most of the cases of paralytic 
poliomyelitis in recent years occurred in these 
populations.
With widespread use of poliovirus vaccine, 
laboratory surveillance of enteroviruses indicates that 
circulation of wild polioviruses has diminished 
markedly. It can be assumed that inapparent infections 
with wild strains will no longer contribute significantly 
to maintaining immunity; therefore, it is essential not 
only to continue active immunization programs for 
infants and children but also to make special efforts to 
raise the low immunization rates existing in certain 
other segments of the population.
POLIOVIRUS VACCINES
Between 1955, when 1PV was introduced, and 1962, 
when live, attenuated vaccines became widely used, 
more than 400 million doses of 1PV were distributed in 
the United States. Primary immunization with IPV plus 
regular booster doses provided a high degree of 
protection against paralytic disease.
OPV has almost completely replaced IPV in this 
country because it is easier to administer and produces 
an immune response like that induced by natural 
poliovirus infection.
Monovalent OPV types 1,2, and 3 were widely used 
in the United States beginning in 1961, but they have 
generally been supplanted by trivalent OPV because of 
greater simplicity in scheduling and recordkeeping.
A primary series of 3 adequately spaced doses of
‘ Official names: (1) Poliovirus Vaccine, Live, Oral, Type 1, 
(2) Poliovirus Vaccine, Live, Oral, Type 2, (3) Poliovirus Vac­
cine, Live, Oral, Type 3, (4) Poliovirus Vaccine, Live, Oral, 
Trivalent.
“ Official name: Poliomyelitis Vaccine.
trivalent OPV will produce an immune response to the 
3 poliovirus types in well over 90 percent of recipients.
Very rarely, paralysis has occurred in recipients of 
OPV or in their close contacts within 2 months of its 
administration. During 1963-70, about 147 million 
doses of trivalent OPV were distributed in the United 
States. In the same 8-year period, 9 cases of 
“ vaccine-associa ted”  paralysis in recipients 
(0.06/million doses distributed) and 21 in contacts of 
recipients (0.14/million doses distributed) were 
reported.
In 1972, OPV produced in the WI-38 strain of 
human diploid cells was licensed in the United States. 
This vaccine is considered to be equivalent in safety 
and effectiveness to vaccine produced in primary rhesus 
monkey kidney cell culture.
VACCINE USAGE
Trivalent OPV-Primary Immunization
Infants: The 3-dose immunization series should be 
started at 6-12 weeks of age, commonly with the first 
dose of DTP. The second dose should be given not less 
than 6 and preferably 8 weeks later. The third dose is an 
integral part of primary immunization and should be 
administered 8-12 months after the second dose.
Children and adolescents; For unimmunized children 
and adolescents through high school age, the primary 
series is 3 doses. The first 2 should be given 6-8 weeks 
apart, and the third, 8-12 months after the second. If 
circumstances do not permit the optimal interval 
between the second and third doses, the third may be 
given as early as 6 weeks after the second.
Adults: Routine poliomyelitis immunization for
adults residing in the continental United States is not 
necessary because of the extreme unlikelihood of 
exposure. However, an unimmunized adult at increased 
risk through contact with a known case or travel to areas 
where polio is epidemic or occurs regularly should 
receive trivalent OPV as indicated for children and 
adolescents. Persons employed in hospitals, medical 
laboratories, and sanitation facilities might also be at 
increased risk, especially if poliomyelitis is occurring in 
the area.
Pregnancy is not an indication for vaccine admini­
stration, nor is it a contraindication when protection is 
required.
Monovalent OPV—Primary Immunization
An alternative primary immunization is 1 dose of 
each of the 3 types of monovalent OPV given at 6 -8 
week intervals. A dose of trivalent OPV should be given
8-12 months after the third dose of monovalent OPV 
to ensure adequate responses to all poliovirus types.
OPV—Booster Doses
Entering school: On entering kindergarten or first 
grade, all children who have completed the primary 
series of OPV should be given a single dose of trivalent 
OPV; others should complete the primary series.
There is no indication for routine booster doses of 
OPV beyond that given at the time of entering school.
Increased risk: A single dose of trivalent OPV can be 
administered to anyone who has completed the full 
primary series because of travel or occupational hazard 
as described above. The need for such an additional dose 
has not been established, but if there is uncertainty 
about the adequacy of existing protection, a single dose 
of trivalent OPV should be given.
Contraindications
Altered immune states: Infection with live,
attenuated polioviruses might be potentiated by severe 
underlying diseases, such as leukemia, lymphoma, or 
generalized malignancy, or by lowered resistance, such as 
from therapy with steroids, alkylating drugs, anti­
metabolites, or radiation; therefore, vaccination of such 
patients should be avoided.
EPIDEMIC CONTROL
For operational purposes in the United States, an 
“epidemic” of poliomyelitis is defined as 2 or more cases 
caused by the same poliovirus type and occurring within 
a 4-week period in a circumscribed population, such as 
that of a city, county, or a metropolitan area. An 
epidemic can be controlled with either trivalent OPV, or. 
after identification of the responsible type of poliovirus, 
homotypic monovalent OPV. Within the epidemic area, 
all persons over 6 weeks of age who have not been 
completely immunized or whose immunization status is 
unknown should promptly receive OPV.
SIMULTANEOUS ADMINISTRATION OF 
LIVE VIRUS VACCINES
There are obvious practical advantages to 
adm in istering  2 or more live virus vaccines 
simultaneously. Data from specific investigations are not 
yet sufficient to develop comprehensive recommenda­
tions on simultaneous use, but a summary of current ex­
perience, attitudes, and practices provides useful guid­
ance.
It has been generally recommended that live virus 
vaccines be given at least I month apart whenever 
possible-the rationale for this being that more frequent 
and severe adverse reactions as well as diminished 
antibody responses otherwise might result. Field 
observations indicate, however, that with simultaneous 
administration of certain live virus vaccines, results of 
this type have been minimal or absent.
If the theoretically desirable I-month interval is not 
feasible, as with the threat of concurrent exposures or 
disruption of immunization programs, the vaccines 
should preferably be given on the same day-at different 
sites for parenteral products.Mil interval of about 2 
days to 2 weeks should be avoided because interference 
between the vaccine viruses is most likely then.
Published: Supplement to the Poliomyelitis Surveillance Unit 
Report No. 285. 1964; revised MMWR Vol 16 No. 33, 1967; 
revised Vol IS No. 43-Supp 1969: revised Vol 21 No. 25-Supp 
1972.
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STATE EPIDEMIOLOGISTS
Key to all disease surveillance activities are those in each State who serve the function as State epidemiologists. 
Responsible for the collection, interpretation and transmission of data and epidemiologic information from their 
individual States, the State epidemiologists perform a most vital role. Their major contributions to the evolution of 
this report are gratefully acknowledged.
Alabama ................................................................................................................................................................................ Frederick S. Wolf, M.D.
A la s k a ................................................................................................................................................................................ Donald K. Freedman, M.D.
Arizona ............................................................................................................................................................................Philip M. Hotchkiss, D .V.M .
Arkansas ...................................................................................................................................................................... Andrew G. Dean, M.D., Acting
C a lifo rn ia ...............................................................................................................................................................................................James Chin, M.D.
C o lo r a d o .......................................................................................................................................................................Thomas M. Vernon, Jr., M .D.
C o n n e c tic u t...................................................................................................................................................................................... James C. Hart, M .D.
D e la w a r e ................................................................................................................................................................................. Ernest S. Tierkel, V.M .D.
District of C o lu m b ia ....................................................................................................................................................Samuel Khoury, M.D., Acting
F lo r id a ..................................................................................................................................................................................... Chester L. Nayfield, M.D.
G e o rg ia ........................................................................................................................................................................................John E. McCroan, Ph.D.
H a w a i i .............................................................................................................................................................................................. Ned Wiebenga, M.D.
Idaho ..........................................................................................................................................................................................John A. Mather, M.D.
I l l i n o i s ........................................................................................................................................................................................... Byron J. Francis, M .D.
In d ia n a ..................................................................................................................................................................................... Charles L. Barrett, M.D.
I o w a ....................................................................................................................... ..................................................................Charles A. Herron, M.D.
K a n s a s ...............................................................................................................................................................................................Don E. Wilcox, M.D.
K e n tu c k y ................................................................................................................................................................................ Calixto Hernandez, M.D.
L o u is ia n a ...........................................................................................................................................................................Charles T . Caraway, D.V.M.
Maine ............................................................................................................................................................................................Peter J. Leadley, M.D.
M a r y la n d .............................................................................................................................................................................................Anita Bahn, M.D.
Massachusetts ...................................................................................................................................................................... Nicholas J. Fiumara, M.D.
Michigan ................................................................................................................................................................................ Norman S. Hayner, M.D.
M in n eso ta ............................................................................................................................................................................................ D. S. Fleming, M.D.
Mississippi .............................................................................................................................................................................Durward L. Blakey, M.D.
Missouri ................... .... .............................................................................................................................................. .......  Denny Donnell, Jr., M.D.
Montana ................................................................................................................................................................................... Martin D. Skinner, M.D.
N e b r a s k a .................................................................................................................................................................................................... Paul A. Stoesz, M.D.
N e v a d a .................................................................................................................................................................................... William M. Edwards, M.D.
New Hampshire ........................................................................................................................................................................... Vladas Kaupas, M .D.
New Jersey ................................................................................................................................................................................... Ronald Altman, M.D.
New M e x ic o ........................................................................................................................................................ Charles F. von Reyn, M.D., Acting
New York State ....................................................................................................................................................Donald O. Lyman, M.D., Acting
New York C i t y .......................................................................................................................................................................Pascal J. Imperato, M .D.
North C a r o lin a .......................................................................................................................................................................... Martin P. Hines, D .V.M .
North Dakota ..................................................................................................................................................................................... Kenneth Mosser
O h i o ........................................................................................................................................................................................... John H. Ackerman, M.D.
O k la h o m a ................................................................................................................................................................................... Stanley Ferguson, Ph.D.
O r e g o n ...........................................................................................................................................................................................John A. Googins, M.D.
Pennsylvania...............................................................................................................................................................................W. D. Schrack, Jr., M.D.
Puerto R i c o .............................................................................................................................................................................................Angel M. Ayala, M.D.
Rhode Island ....................................................................................................................................................Michael P. Hudgins, M.D., Acting
South C a r o lin a ........................................................................................................................................................................ William B. Gamble, M.D.
South Dakota .........................................................................................................................................................................Robert S. Westaby, M.D.
Tennessee.................................................................................................................................................................. Robert H. Hutcheson, Jr., M.D.
Texas ............................................................................................................................................................................................ M. S. Dickerson, M.D.
U t a h .............................................................................................................................................................................................. .Taira Fukushima, M.D.
Vermont ....................................................................................................................................................................... ...  . . Geoffrey Smith, M.D.
Virginia ........................................................................................................................... Robert S. Jackson, M.D.
Washington .................................................................................................................................................................................Thieu Nghiem, M.D.
West Virginia ..................................................................................................................................................................................... N. H. Dyer, M .D.
W iscon s in .................................................................................................................................................................................H. Grant Skinner, M.D.
W y o m in g .................................................................................................................................................................................Herman S. Parish, M.D.
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